StockData
Neogen Corp logo

Neogen Corp (NEOG) stock

NEOGNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends May 31
Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 7, 2026Score 7/3049% above fair value
$10.90+0.02 (+0.18%)

Close on Nov 17, 2026Market cap $2.38BP/E –Yield –

Neogen total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Neogen's total debt was $1.55B at Aug 31, 2026. For fiscal 2026 it was $1.59B, up 78.2% from the year before. The highest annual figure on record is $1.79B in fiscal 2023.

Annual total debt

PeriodPeriod endValueChange
FY2026May 31, 2026$1.59B+78.2%
FY2025May 31, 2025$894.10M+0.4%
FY2024May 31, 2024$890.84M-50.1%
FY2023May 31, 2023$1.79B–
FY2022May 31, 2022$0–

Quarterly total debt

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2027CQ3 2026Aug 31, 2026$1.55B-2.4%
Q4 FY2026CQ2 2026May 31, 2026$1.59B+78.2%
Q3 FY2026CQ1 2026Feb 28, 2026$1.59B+78.9%
Q2 FY2026CQ4 2025Nov 30, 2025$1.59B+79.0%
Q1 FY2026CQ3 2025Aug 31, 2025$1.59B+79.1%
Q4 FY2025CQ2 2025May 31, 2025$894.10M+0.4%
Q3 FY2025CQ1 2025Feb 28, 2025$890.61M+0.0%
Q2 FY2025CQ4 2024Nov 30, 2024$889.87M+0.0%
Q1 FY2025CQ3 2024Aug 31, 2024$889.13M+0.0%
Q4 FY2024CQ2 2024May 31, 2024$890.84M-50.1%
Q3 FY2024CQ1 2024Feb 29, 2024$890.17M+0.6%
Q2 FY2024CQ4 2023Nov 30, 2023$889.48M-3.7%
Q1 FY2024CQ3 2023Aug 31, 2023$888.82M–
Q4 FY2023CQ2 2023May 31, 2023$1.79B–
Q3 FY2023CQ1 2023Feb 28, 2023$884.70M–
Q2 FY2023CQ4 2022Nov 30, 2022$923.96M–
Q4 FY2022CQ2 2022May 31, 2022$0–

More Neogen figures

See a number that looks wrong?